Among them, the incidence rates of different molecular subtypes in all BC patients are as follows: luminal A, 104,520 cases (72.8%); luminal B, 16,363 cases (11.4%); HER2-enriched, 6887 cases (4.8%); and triple-negative, 15,793 cases (11%). The gene discussed is ERBB2; the disease is breast cancer.